Novaccess Global Inc. · OTC:XSNX
Novaccess Global — Virtual Investor Summit December 2023
21 slides from Novaccess Global's conference presentation, December 2023
Slide 1: Virtual Investor Summit December 2023
Dwain Irvin, PHD, MPH CEO Virtual Investor Summit December 2023 Confidential and Proprietary. Copyright 2023 NovAccess Global, Inc. All Rights Reserved.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This information package contains forward-looking statements, which includes forecasts and timelines. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “will”, “proposes”, “expects”, “estimates”, “intends”, “anticipate
Slide 3: About Us
About About Us Us Pre-IND stage biotech company developing novel, personalized immunotherapies for brain cancers, glioblastoma Orphan drug-designation, all malignant brain tumors, TLR-AD1 Glioblastoma, 2027, $2.9 Billion Market Size (GlobalData Inc. 2019) An expert scientific and managerial team foc
Slide 4: Our Focused Mission
Our Focused Mission Growth by acquisition of cutting-edge assets Enhance and accelerate bringing to market novel brain Utilization of our expert tumor immunotherapies executive and scientific advisory board 4 Confidential and Proprietary. Copyright 2023 NovAccess Global, Inc. All Rights Reserved.
Slide 5: Glioblastoma Facts
Glioblastoma Facts • More than 20,000 brain tumors diagnoses are estimated annually in the U.S. • Glioblastoma is the most common primary adult brain tumor (e.g. Ted Kennedy, John McCain) • Five-year survival rates are less than 5% for Glioblastoma • Despite 40-year advances in Chemotherapy and Radi
Slide 6: Immunotherapy for Glioblastoma
Immunotherapy for Glioblastoma Problem: No brain cancer immunotherapy in market, to date • Standard of Care: Surgical resection followed by radiation and chemotherapy • 15-month median survival • No Cures: Significant unmet need Opportunities: • Immunotherapy: 3 Major Types 1. Dendritic Cell (DC) 2.
Slide 7: Immunotherapy for Glioblastoma: Dendritic Cell Vaccine
Immunotherapy for Glioblastoma Dendritic Cell Vaccine (1st Generation) • Improves survival in responders (Phase I and II) • Reduces chance of Glioblastoma recurrence • 3rd gen in development – improvement in survival & outcome 7 Confidential and Proprietary. Copyright 2023 NovAccess Global, Inc. All
Slide 8: 3rd Gen vs. 1st Gen Vaccine
3 Gen vs. 1 Gen Vaccine rd st Preclinical Survival Optimization of 3rd Gen TLR-AD1 Vaccine Human Clinical trial on 1st Gen TLR-AD1 vs 1st gen Median Survival P < 0.05 35% • 1st/2nd Gen: 6-7 months longer life 60 81 • 3rd Gen TLR-AD: 13-25 months longer life! *Wheeler et.al. Cancer Res. 2008;68(14):5
Slide 9: Immunotherapy for Glioblastoma: Clinical Procedure
Immunotherapy for Glioblastoma Clinical Procedure: Neurosurgeon isolates Tumor and TUMOR Immune Cells - Sends to Lab TUMOR ANTIGEN CELLS BLOOD ANTIGEN- PRESENTING CELLS (Dendritic Immune Cells) 9 Confidential and Proprietary. Copyright 2023 NovAccess Global, Inc. All Rights Reserved.
Slide 10: Immunotherapy for Glioblastoma: 1st Generation
Immunotherapy for Glioblastoma Generation 1 TUMOR CELL FRAGMENTS (Bulk Tumor Lysate Antigen) + IMMUNE CELLS (Dendritic, APC Cells) 10 Confidential and Proprietary. Copyright 2023 NovAccess Global, Inc. All Rights Reserved.
Slide 11: Immunotherapy for Glioblastoma: Step 3
Immunotherapy for Glioblastoma Step 3: 1st Generation Glioblastoma Vaccine Administered Glioma Tumor Cell Lysate Antigen specific or antigens derived from bulk lysate combined. ‘Intelligence-Briefed’ Immune Cells Introduced into Bloodstream T-Cells Trained to Identify Tumor and Anti-Tumor Response I
Slide 12: Immunotherapy for Glioblastoma: 3rd Generation
Immunotherapy for Glioblastoma Generation 3 TUMOR CELL FRAGMENTS (Bulk Tumor Lysate Antigen) + IMMUNE CELLS (Dendritic, APC Cells) + IMMUNE BOOSTERS (Proprietary TLR-AD1) 12 Confidential and Proprietary. Copyright 2023 NovAccess Global, Inc. All Rights Reserved.
Slide 13: Immunotherapy for Glioblastoma: TLR-AD1 Vaccine Administered
Immunotherapy for Glioblastoma Step 3: TLR-AD1 Glioblastoma Vaccine Administered Glioma Tumor Cell Lysate Antigen specific or antigens derived from bulk lysate combined with Toll- like receptor (TLR) adjuvants ‘Intelligence-Briefed’ Immune Cells Introduced into Bloodstream T-Cells Trained to Identif
Slide 14: GBM
A B C GBM IDH1 binds to and enzymatically modifies the CD8 coreceptor on T cells (A), enhancing their killing of tumors. IDH1 overexpression by a mouse glioma increases and IDH1 mutation decreases its sensitivity to vaccine treatment (B). The level of IDH1 in glioblastoma tumor tissue discrimi
Slide 15: Summary
Summary • Parent immunotherapy shows improvement in patient survival over standard of care (chemotherapy and radiation) in Phase I and II Human Clinical trials • TLR-AD1 out-performs parent immunotherapies in pre-clinical animal trials • FDA provides Orphan Drug designation for TLR-AD1, covering all
Slide 16: Immunotherapy for Glioblastoma: Market Analysis
Immunotherapy for Glioblastoma Market Analysis: • 2018, Global, $700M Glioblastoma Treatment Market, CAGR 9.3% (GlobalData Inc. 2019) • 2027, $2.9B Glioblastoma Treatment Market (GlobalData Inc. 2019) • Unmet need - No current immunotherapy for brain tumors • Presumed significant market opportunity
Slide 17: Investor Highlights
Investor Highlights Orphan Drug-Designation in October 2022 Announce Manufacturing Partner 2023 (TBD) Complete Manufacturing Data for IND Application 2024 (Q3) File IND application with FDA in 2024 (TBD) Confidential 2022 17 Confidential and Proprietary. Copyright 2023 NovAccess Global, Inc. All Rig
Slide 18: Our Team
Our Team Each Contributor, an Expert in their Field - Highly Focused, yet Adaptable Management Board of Directors Scientific Advisory Board John Cassarini Andrew Norris Ph.D. Portfolio Management Renard Currie MBA Co-Founder, Midvale Group Dwain Irvin Ph.D., MPH Executive, XSNX Board Manages product
Slide 19: Thank You!
Thank You! Confidential and Proprietary. Copyright 2023 NovAccess Global, Inc. All Rights Reserved. novaccessglobal.com
Slide 20: Company Highlights
Company Highlights • Filing IND application to obtain FDA approval for human clinical trial (TBD) 2023 • Partners with BCN Biosciences to expand immunotherapy platform • Partners with CKN Ventures to expand new Precision Medicine Division YE 2022 Acquisition Partnering of with manufacturing cutting-
Slide 21: Milestones Achieved
Milestones Achieved Initiated recapitalization of company; expected to be completed with diversification of 2022 shareholder base as XSNX shares are distributed to Innovest shareholders FDA pre-IND interaction: FDA states that XSNX is not required to do additional pre-clinical 2021 R&D studies and p
NovAccess Global — Virtual Investor Summit December 2023 on 6ix